WhatPeptide

Tesamorelin

A stabilized GHRH analog approved for reduction of excess visceral fat in HIV-associated lipodystrophy.

Strong evidence FDA Approved GH Secretagogue

Written by WhatPeptide Editorial Team · Last updated 2026-03-17

Half-life

Mean 8 minutes (healthy subjects); GH axis effects persist longer

Dosage range

2 mg once daily (clinical literature context)

Administration

Subcutaneous injection

Research level

Strong

How Tesamorelin works

Tesamorelin stimulates pituitary GHRH receptors to increase endogenous GH pulsatility and IGF-1 levels. Clinical trials in HIV-associated lipodystrophy show reductions in visceral adipose tissue. Endocrine effects require monitoring, especially with glucose metabolism risks.

Also known as: Egrifta, TH9507

Research relevance

GH Boost
Strong research relevance 85
Fat Loss
Moderate relevance 65
Muscle Growth
Some relevance 45
Anti-Aging & Longevity
Some relevance 45
Recovery & Healing
Some relevance 40
Sleep & Relaxation
Some relevance 40
Cognition & Focus
Some relevance 20
Sexual Health
Some relevance 20

Side effects & safety

Injection-site reactions Arthralgia Edema Glucose elevation

Contraindications

Pregnancy
Active malignancy
Untreated pituitary disease

Consult a healthcare provider before use if any of these apply to you.

Key studies

FAQ

What is Tesamorelin? +
A stabilized GHRH analog approved for reduction of excess visceral fat in HIV-associated lipodystrophy. Its mechanism of action is supported by robust clinical evidence.
What is Tesamorelin researched for? +
Tesamorelin has the strongest research relevance for GH Boost, Fat Loss, Muscle Growth. Evidence is supported by robust clinical evidence.
What are the side effects of Tesamorelin? +
Reported side effects include Injection-site reactions, Arthralgia, Edema, Glucose elevation. Key contraindications: Pregnancy; Active malignancy; Untreated pituitary disease.
Is Tesamorelin FDA approved? +
Yes, Tesamorelin has FDA approval for specific indications. Always consult a healthcare provider for appropriate use.
How is Tesamorelin administered? +
Tesamorelin is typically administered via subcutaneous route. Researched dosage range: 2 mg once daily (clinical literature context). Half-life: Mean 8 minutes (healthy subjects); GH axis effects persist longer.

Explore similar peptides

CJC-1295

Moderate evidence

GH Secretagogue

A modified GHRH analog designed to prolong endogenous GH pulse support through albumin binding (DAC form). Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.

CJC-1295 (No DAC)

Moderate evidence

GH Secretagogue

CJC-1295 without DAC (also called Modified GRF 1-29) is a GHRH analog with a shorter half-life than the DAC version, making it preferred for mimicking pulsatile physiological GH release when administered with a GHRP. It is widely used in research and wellness contexts for GH optimization.

MK-677

Moderate evidence

GH Secretagogue

An oral non-peptide ghrelin receptor agonist often discussed with GH peptides due to GH/IGF-1 stimulating effects. Placed on FDA Category 2 list (September 29, 2023) as 'Ibutamoren mesylate.'

Sermorelin

Strong evidence

GH Secretagogue

FDA-approved as GEREF for diagnosis and treatment of growth hormone deficiency in children (NDA 20-443, approved September 26, 1997). Voluntarily withdrawn from market June 2009 for commercial reasons — not for safety or efficacy concerns (Federal Register 78 FR 14095, March 4, 2013). Remains compoundable under Section 503A.